G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.

摘要: Febrile neutropenia (FN) is a common complication among patients with chemotherapy-induced myelotoxicity and associated number of negative outcomes including prolonged hospitalization, increased medical costs, risk mortality, dose reductions, delays. Granulocyte-colony-stimulating factor (G-CSF), granulocyte–macrophage-colony stimulating (GM-CSF), pegylated G-CSF are effective at reducing duration neutropenia-related events. However, despite guidelines, the use in United States has not been consistent pattern care studies have focused primarily on G-CSF. A found that underutilized undergoing chemotherapy treatments high FN, while being over utilized low-risk FN. Wide variations overuse, underuse, misuse physician patient factors. Improved awareness feedback to providers regarding proper usage, understanding regimens very low risks as well (>20%) FN some approaches could lead improving care.